Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805244 · ClinicalTrials.gov registry record · Phase 1
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02805244 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 6 participants.
The verdict
NCT02805244, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolite(s).
Interventions
- DRUG JTZ-951, 14C-JTZ-951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02805244
The ClinicalTrials.gov registry entry for NCT02805244 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JTZ-951, 14C-JTZ-951 is the first listed.
NCT02805244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02805244 about?
NCT02805244 is a clinical study titled "Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis". A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolit...
What is the current status of trial NCT02805244?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02805244?
The interventions under investigation include: JTZ-951, 14C-JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT02805244?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.